Suppr超能文献

抗疟疾抗癌药物:是时候重新审视了吗?

Anticancer agents against malaria: time to revisit?

机构信息

Kenya Medical Research Institute (KEMRI)/Wellcome Trust Collaborative Research Programme, Kilifi, Kenya.

出版信息

Trends Parasitol. 2010 Mar;26(3):125-9. doi: 10.1016/j.pt.2009.12.002. Epub 2010 Jan 6.

Abstract

The emergence of artemisinin resistance could adversely impact the current strategy for malaria treatment; thus, new drugs are urgently needed. A possible approach to developing new antimalarials is to find new uses for old drugs. Some anticancer agents such as methotrexate and trimetrexate are active against malaria. However, they are commonly perceived to be toxic and thus not suitable for malaria treatment. In this opinion article, we examine how the toxicity of anticancer agents is just a matter of dose or 'only dose makes the poison', as coined in Paracelsus' law. Thus, the opportunity exists to discover new antimalarials using the anticancer pharmacopoeia.

摘要

青蒿素耐药性的出现可能会对当前的疟疾治疗策略产生不利影响;因此,急需新的药物。开发新的抗疟药物的一种可能方法是寻找旧药物的新用途。一些抗癌药物,如甲氨蝶呤和三氨蝶呤,对疟疾具有活性。然而,它们通常被认为是有毒的,因此不适合用于疟疾治疗。在这篇观点文章中,我们探讨了抗癌药物的毒性如何只是剂量的问题,或者像帕拉塞尔苏斯定律所指出的那样,“只有剂量才能使毒物变成药物”。因此,利用抗癌药物学发现新的抗疟药物是有可能的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aba4/2927876/52d8fe48d3d1/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验